Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.
"These three presentations demonstrate our commitment to furthering the body of scientific knowledge surrounding SB 9200 and its antiviral activity," said R.P. Iyer, Ph.D., Co-founder and Chief Scientific Officer of Spring Bank. "The data being presented support our pipeline of clinical-stage candidates and provide important insights that are relevant to our ongoing clinical development in viral infections, including HBV and HCV, among others. ICAR is a prestigious global antiviral conference and we are proud to have been selected as one of the presenting companies."
The details of Spring Bank's presentations are below:
Oral poster presentations
- "Activation of Intracellular Viral Sensors by the Anti-Hepatitis Agent SB 9200 – Implications for Broad-Spectrum Antiviral Activity"
- "Preclinical Studies of SB 9200 as an Antiviral Agent Against HBV and HCV"
Poster presentation
- "SB 9200, a Novel Anti-HBV agent – In Vitro Combination Studies and Pharmacodynamic studies in Woodchucks"
Expanding access to GLP-1 weight-loss drugs could save thousands of lives